Skip to main content
. 2021 Aug 13;10(8):2087. doi: 10.3390/cells10082087

Figure 7.

Figure 7

Combined galunisertib and IR treatment promoted antitumor activity in CRC cells. HCT116 cells were treated with galunisertib (10 µmol/L) alone, IR (5 Gy) alone, or combined for 24 h. (a) Western blot analysis was used to assess PODXL, vimentin, E-cadherin, and p-FAK expressions (b) HCT116 cells were treated with galunisertib (10 μM) alone, IR (5 Gy) alone, or combined for 24 h. Twenty-four hours after treatment, cell viability was estimated using a CCK-8 assay. The graph indicates cell viability from three independent experiments ± SD. *** p < 0.005. (c) C HCT116 cells were treated with galunisertib (10 µmol/L) alone, IR (5 Gy) alone, or combined for 21 days. The colony number was calculated from three replicate plates of three independent experiments; bars indicate SD. Representative images from 21 days post-plating are shown. (d) Cell migration was assessed using a transwell assay. The data shown are representative of three independent experiments. *** p < 0.005, ** p < 0.01, and * p < 0.05. (e) Representative images of the dissemination of HCT116 spheroids over a 3-day culture, in which cells were treated with IR, galunisertib, or combined treatment from day 0. Scale bar, 200 μm. The data shown are representative of three independent experiments. *** p < 0.005, ** p < 0.01, and * p < 0.05.